Anticancer virus therapy rallies killer immune cells against myeloma
Early trial data show pelareorep activates cancer-fighting cells in tough cases
Written by |
The experimental therapy pelareorep was found to trigger an increase in levels of cancer-killing immune cells in people with hard-to-treat myeloma. (Photo from iStock)
The experimental anticancer virus therapy pelareorep can trigger an increase in the levels of cancer-killing immune cells in people with hard-to-treat myeloma, according to new clinical trial data from its developer Oncolytics Biotech.
Oncolytics announced it will present the findings next month at the 68th American Society of Hematology Annual Meeting and Exposition.
“These single-cell sequencing data provide evidence that pelareorep can enhance immunological activity within the tumor microenvironment, demonstrating its potential immunotherapeutic activity and supporting further evaluation in combination with other immune-based treatments,” Thomas Heineman, MD, PhD, chief medical officer of Oncolytics, said in a company press release.
How pelareorep targets myeloma
Pelareorep is an oncolytic virus — that is, a virus designed to preferentially infect and kill cancer cells. The therapy, which is administered by infusion into the bloodstream, aims to fight cancer with a two-pronged attack. First, the virus itself infects the cancer cells, killing some in the process. Then the body’s immune system is activated to eliminate the remaining virus-infected cancer cells.
Specifically, pelareorep aims to activate CD8 T-cells, a specific type of immune cell that acts like the body’s assassins, killing cells that have become infected with viruses. Oncolytics is developing the therapy for myeloma and other blood cancers, as well as solid tumors including pancreatic cancer.
The new data come from an ongoing Phase 1b/2 clinical trial called AMBUSH (NCT05514990), sponsored by the University of Southern California. The study enrolled 10 people whose myeloma had returned or failed to respond after three to 11 prior treatments. All participants received the approved myeloma therapies Velcade (bortezomib) and dexamethasone, along with pembrolizumab, an immune-stimulating drug approved for several other cancers under the brand name Keytruda, though not yet approved in the U.S. for myeloma.
Some of the participants also received treatment with pelareorep. According to Oncolytics, data from the trial indicate that the viral treatment increased levels of killer CD8 cells, and these increases were greater among patients with a clinical response to therapy. Other immune cells also showed changes consistent with increased anticancer activity, while myeloma cells showed increased markers of cell death.
“These changes are consistent with pelareorep’s mechanism of action and ability to remodel the tumor microenvironment,” Heineman said.
Leave a comment
Fill in the required fields to post. Your email address will not be published.